# BEAM — Beam Therapeutics · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BEAM  
**Sources:** 21  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-beam-beam-therapeutics-catalysts-narrative-risks-6630

---

## Beam Therapeutics (BEAM) — Point-in-Time Research as of 2026-11-10

Note: figures below are compiled from the provided sources and are not a recommendation.

**Quick facts:** Market cap ~$2.73B, 103.5M shares outstanding, ~$26.41 closing price on Nov 6, 2026 [[10]](https://www.biotechdistilled.com/BEAM/); trading around $26–27 [[6]](https://www.rttnews.com/3707887/beam-therapeutics-plans-beam-304-phase-1-2-trial-in-pku-for-early-2027-stock-up.aspx)[[10]](https://www.biotechdistilled.com/BEAM/). NASDAQ-listed, Healthcare/Biotechnology [background].

## Recent catalysts (last ~1–3 months, Aug–Nov 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-beam-beam-therapeutics-catalysts-narrative-risks-6630 (free to sign up)._
